Research programme: renin inhibitors 500 series - Roche/Speedel

Drug Profile

Research programme: renin inhibitors 500 series - Roche/Speedel

Alternative Names: SPP 500

Latest Information Update: 12 Oct 2007

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Roche
  • Developer Speedel Development
  • Class
  • Mechanism of Action Renin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hypertension

Most Recent Events

  • 05 Apr 2006 This programme is still in active development - (BIO-Europe-2005)
  • 11 May 2005 This programme is still in active development - (BioSquare-2005)
  • 04 Apr 2002 Preclinical trials in Hypertension in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top